Antiemetics for reducing vomiting related to acute ... - Update Software

Cubeddu 1997 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly assigned
to receive either....” Pg 186
Comment: unclear.
Allocation concealment (selection bias) Low risk Quote: “The study medication was prepared
by a pharmacist not involved in patient
care...” Pg 186
Comment: probably done.
Blinding of participants and personnel
(performance bias)
All outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Participants: not applicable.
Healthcare providers:
Comment: unclear how knowledge of the
allocated interventions by the personnel
was adequately prevented during the study
Unclear risk Outcomes assessors & data analysts: not reported
if persons assessing the outcomes of
care were blinded to which treatment the
participants received
Low risk All data appear to have been reported in the
study outcomes.
Selective reporting (reporting bias) Low risk No evidence of selective reporting. Outcomes
listed in the methods section were
comparable to those reported
Other bias High risk The authors reported a baseline imbalance
in age; weight; and height between the
ondansetron and placebo treatment arm.
Mean age yrs (range); ondansetron 1.0 (0.
5 to 2), metoclopramide 1.8 (0.5 to 8) and
placebo 2.5 (0.5 to 8). (See Table 18).
This imbalance was not adjusted for in the
analysis.
The trialists reported that the study was
supported by Glaxo Wellcome and although
the level of support was unclear two
of the investigators were in the employment
of Glaxo Wellcome
Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
29